Evidence map›Paper›PMID 33634987›Full record

ArticleClinical and translational medicine2021

Forty-three key gene expressions involved in the effect of indoleamine 2,3-dioxygenase 1 expression on cancer prognosis may be a potential indoleamine 2,3-dioxygenase 1 inhibitor biomarker.

Weirui Li, Leilei Guo, Zikang Xing, Xin Fang, Heng Liang, Shengnan Zhang, Lei Shi, Chunxiang Kuang, Leming Shi, Yuanting Zheng and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Molecular Pharmacology at the Crossroads of Precision Medicine.Current issues in molecular biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Weirui LiState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Leilei GuoState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Zikang XingState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Xin FangState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Heng LiangState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Shengnan ZhangState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Lei ShiState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Chunxiang KuangShanghai Key Lab of Chemical Assessment and Sustainability, School of Chemical Science and Engineering, Tongji University, Shanghai, China.
Leming ShiState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Yuanting ZhengState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Yueqing HuState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Qing YangState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.ORCID 0000-0003-4162-922X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene Expression Regulation, NeoplasticGenes, NeoplasmGenetic MarkersHumansIndoleamine-Pyrrole 2,3,-DioxygenaseKaplan-Meier EstimateNeoplasmsPrognosisProportional Hazards ModelsGenetic MarkersIDO1 protein, humanIndoleamine-Pyrrole 2,3,-Dioxygenase

Identifiers

PMID33634987
PMCPMC7888544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.